Nimbus Lakshmi
About Nimbus Lakshmi
Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
Canonical: https://fsome.com/organization/nimbus-lakshmi-2872829 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.